Advertisement

European Journal of Clinical Pharmacology

, Volume 7, Issue 5, pp 343–346 | Cite as

Therapeutic effectivenss and plasma levels of aprindine, a new antidysrhythmic drug

  • J. P. Van Durme
  • M. G. Bogaert
  • M. T. Rosseel
Originals

Summary

41 patients with stable, frequent, chronic premature ventricular contractions have been treated with aprindine, and its therapeutic effectiveness evaluated by continuous electrocardiographic recording on tape. Excellent results (total suppression of the dysrhythmia) were obtained in 29 patients (71%), in whom the minimal effective plasma level ranged from 0.73 to 2.55 µg/ml (mean 1.35 µg/ml). Neurological side effects developed in 9 patients (22%), with plasma levels from 1.19 to 4.13 µg/ml (mean 2.65 µg/ml). The value of plasma level determinations is discussed.

Key words

Premature ventricular contractions continuous electrocardiography aprindine antidysrhythmics plasma level neurological side effects 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Atkinson, A. J.: Clinical use of blood levels of cardiac drugs. Mod. Conc. cardiov. Dis.42, 1–4 (1973)Google Scholar
  2. 2.
    Bloomfield, S. S., Romhilt, D. W., Te-Chuan-Chou, Flowler, N. O.: Quinidine for prophylaxis of arrhythmias in acute myocardial infarction. New Engl. J. Med.285, 979–986 (1971)Google Scholar
  3. 3.
    Dodion, L., De Suray, J. M., De Blecker, M., Georges, A.: Caractéristiques pharmacocinétiques et biodégradation de l'aprindine chez l'homme. Therapie (In press)Google Scholar
  4. 4.
    Dollery, C. T.: Pharmacokinetics — Master or Servant? Eur. J. clin. Pharmacol.6, 1–2 (1973)Google Scholar
  5. 5.
    Fassola, A. F.: The pharmacology and clinical evaluation of aprindine. A new antiarrhythmic agent. Acta Cardiol. (Brux.) In pressGoogle Scholar
  6. 6.
    Georges, A., Hosslet, A., Duvernay, G.: Pharmacological evaluation of aprindine (AC 1802) a new antiarrhythmic agent. Acta Cardiol. (Brux.)28, 166–191 (1973)Google Scholar
  7. 7.
    Holter, N. J.: New method for heart studies. Science134, 1214–1220 (1961)Google Scholar
  8. 8.
    Kesteloot, H., Van Mieghem, W., De Geest, H.: Aprindine (AC 1802) a new antiarrhythmic drug. Acta Cardiol. (Brux.)28, 145–165 (1973)Google Scholar
  9. 9.
    Koch-Weser, J., Klein, S. W., Foo-Canto, L. L., Kastor, J. A., Desanctis. R. W.: Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction. New Engl. J. Med.281, 1253–1260 (1969)Google Scholar
  10. 10.
    Koch-Weser, J., Klein, S. W.: Procainamide dosage schedules, plasma concentrations and clinical effects. J. Amer. med. Ass.215, 1454–1460 (1971)Google Scholar
  11. 11.
    Lown, B., Vassaux, C.: Lidocaine in acute myocardial infarction. Amer. Heart J.76, 586–587 (1968)Google Scholar
  12. 12.
    Lown, B., Wolf, M.: Approaches to sudden death from coronary heart disease. Circulation44, 130–142 (1973)Google Scholar
  13. 13.
    Melmon, K. L., Morrelli, H. F.: Clinical Pharmacology, p. 186. New York: Macmillan 1972Google Scholar
  14. 14.
    Sjöqvist, F., Beryilsson, L.: Plasma concentrations of drugs and pharmacological response in man. In “Biological effects of drugs in relation to their plasma concentrations”, p. 25–40. London and Basingstoke: Macmillan 1973Google Scholar
  15. 15.
    Van Durme, J. P., Rosseel, M.-T., Bogaert, M. G.: Therapeutic effectiveness and plasma levels of a new antidysrhythmic drug: aprindine. Acta Cardiol. (Brux.) (In press)Google Scholar
  16. 16.
    Van Durme, J. P., Rousseau, M., Mbuyamba, P.: Treament of chronic ventricular dysrhythmias with a new drug: aprindine (AC 1802). Acta Cardiol. (Brux.) (In press)Google Scholar
  17. 17.
    Veronck, F., Vereecke, J., Vleugels, A.: Electrophysiological effects of aprindine on isolated heart preparations. Eur. J. Pharmacol.26, 338–347 (1974)Google Scholar

Copyright information

© Springer-Verlag 1974

Authors and Affiliations

  • J. P. Van Durme
    • 1
  • M. G. Bogaert
    • 1
  • M. T. Rosseel
    • 1
  1. 1.Department of Cardiology and Heymans, Institute of PharmacologyUniversity of Gent, Akademisch ZiekenhuisGentBelgium

Personalised recommendations